BioCentury
ARTICLE | Clinical News

Luminate: Phase IIb data

October 24, 2016 7:00 AM UTC

The double-blind, U.S. Phase IIb DEL MAR trial in 136 DME patients showed that once-monthly 1 mg Luminate met the primary endpoint of non-inferiority to Avastin bevacizumab in the mean improvement fro...